Boehringer Ingelheim
For Healthcare Professionals
updated banner-jardiance-new

Prof. Sarah Jarvis on Empagliflozin as CRM Medication

05/02/2025 | Author: Boehringer Ingelheim

Document ID: PC-PH-106204

Experts videos

What is the Mechanism of Jardiance in HF - Prof. Januzzi
Prof. Januzzi Snippet-How safe of Empagliflozin Jardiance in HFrEF
Expert's Video Prof. Zieroth Adhering to early and sustained treatment
Expert's Video Prof. Zieroth Addressing hurdles in adopting CRM Management
Expert's Video Prof. Zieroth Value of GDMT to achieve outcomes in CRM
Expert's Video Prof. Zieroth Starting on Empa for T2D patients to address HF risk
Expert's Video Prof. Zieroth Safety in HF with T2D
Prof. Melanie Davies on Early Initiation of Empagliflozin
Prof. Melanie Davies - T2D Guidelines Recommendation
Prof. Melanie Davies on Empagliflozin as CRM Medication
Prof. Roger Chen on Early Initiation of Empagliflozin
Prof. Roger Chen on Empagliflozin as CRM Medication
Prof. Sarah Jarvis on Early Initiation of Empagliflozin
Prof. Sarah Jarvis on Empagliflozin as CRM Medication
Empagliflozin to Start Treatment Management
What differentiates Empagliflozin from other generic SGLT2is?
HF Video Prof. Roger Chen - Importance of Catching HF patients early in hospital
HF Video Prof. Sarah Jarvis - Capturing HF patients early in the hospital
HF Video Prof. Sarah Jarvis - Empowering PCPs in HF
HF Video Prof. Melanie Davies - Jardiance safety for HF patients with T2D

RELATED CONTENT